The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Sylvie Rottey
No Relationships to Disclose
 
Ana Aparicio
Honoraria - American Cancer Society; Amgen; Astellas Pharma; AstraZeneca; Biosense Webster (I); Boston Scientific (I); Daiichi Sankyo Inc; Janssen Research & Development
Consulting or Advisory Role - American Cancer Society; Amgen; Astellas Pharma; AstraZeneca; Biosense Webster (I); Boston Scientific (I); Daiichi Sankyo Inc.; Janssen Research & Development
Speakers' Bureau - Biosense Webster (I); Boston Scientific (I)
Research Funding - BioSense Webster (I); Boston Scientific (I); Bristol-Myers Squibb (Inst); Hansen Medical (I); Janssen (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Two (I)
Travel, Accommodations, Expenses - Biosense WEbster (I)
 
Richard Greil
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Melissa Andrea Reimers
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb/Pfizer (Inst); FORMA Therapeutics (Inst)
 
Shahneen Kaur Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharpe & Dohme (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
 
Yiran Zhang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Mark Salvati
Employment - Amgen
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Amgen; Bristol-Myers Squibb; Johnson & Johnson
 
Nooshin Hashemi Sadraei
Employment - Amgen
Stock and Other Ownership Interests - Amgen